Goldman Sachs initiated coverage of Ardent Health (ARDT) with a Neutral rating and $19 price target The firm sees favorable trends continuing for the hospital sector through 2028, including supportive labor dynamics, tailwinds from previously approved pro-utilization government policies, and the industry showing more effective adaptation to structural changes. However, the sector will face new pressures from implementation of the One Big Beautiful Bill, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health Partners Amends Credit Agreements for Flexibility
- Ardent Health Partners: Buy Rating Affirmed Amid Growth Potential and Attractive Valuation
- Ardent Health initiated with a Buy at UBS
- Ardent Health files $500M mixed securities shelf
- Ardent Health files to sell 120.45M shares of common stock for holders